JP2004537289A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537289A5
JP2004537289A5 JP2002588919A JP2002588919A JP2004537289A5 JP 2004537289 A5 JP2004537289 A5 JP 2004537289A5 JP 2002588919 A JP2002588919 A JP 2002588919A JP 2002588919 A JP2002588919 A JP 2002588919A JP 2004537289 A5 JP2004537289 A5 JP 2004537289A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cell
hbm
antibody
lrp6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002588919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/014877 external-priority patent/WO2002092000A2/en
Publication of JP2004537289A publication Critical patent/JP2004537289A/ja
Publication of JP2004537289A5 publication Critical patent/JP2004537289A5/ja
Withdrawn legal-status Critical Current

Links

JP2002588919A 2001-05-11 2002-05-13 骨量および脂質レベルを調整するｈｂｍ変異型 Withdrawn JP2004537289A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29007101P 2001-05-11 2001-05-11
US29131101P 2001-05-17 2001-05-17
US35305802P 2002-02-01 2002-02-01
US36129302P 2002-03-04 2002-03-04
PCT/US2002/014877 WO2002092000A2 (en) 2001-05-11 2002-05-13 Hbm variants that modulate bone mass and lipid levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010146427A Division JP2011004744A (ja) 2001-05-11 2010-06-28 骨量および脂質レベルを調整するｈｂｍ変異型

Publications (2)

Publication Number Publication Date
JP2004537289A JP2004537289A (ja) 2004-12-16
JP2004537289A5 true JP2004537289A5 (enExample) 2005-12-22

Family

ID=27501520

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002589632A Withdrawn JP2005511002A (ja) 2001-05-11 2002-05-13 骨量変調のトランスジェニック動物モデル
JP2002588919A Withdrawn JP2004537289A (ja) 2001-05-11 2002-05-13 骨量および脂質レベルを調整するｈｂｍ変異型
JP2010146427A Pending JP2011004744A (ja) 2001-05-11 2010-06-28 骨量および脂質レベルを調整するｈｂｍ変異型

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002589632A Withdrawn JP2005511002A (ja) 2001-05-11 2002-05-13 骨量変調のトランスジェニック動物モデル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010146427A Pending JP2011004744A (ja) 2001-05-11 2010-06-28 骨量および脂質レベルを調整するｈｂｍ変異型

Country Status (7)

Country Link
US (2) US7416849B2 (enExample)
EP (2) EP1401269A4 (enExample)
JP (3) JP2005511002A (enExample)
AU (2) AU2002308681A1 (enExample)
BR (2) BR0209563A (enExample)
CA (2) CA2446859A1 (enExample)
WO (2) WO2002092000A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
NZ522600A (en) * 2000-05-26 2004-09-24 Genome Therapeutics Corp Regulating lipid levels via the Zmax1 or HBM gene
BR0209563A (pt) 2001-05-11 2004-12-07 Genome Theraupeutics Corp ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
US7514594B2 (en) * 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
EP1395285A4 (en) * 2001-05-17 2005-06-01 Genome Therapeutics Corp REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
FR2856410B1 (fr) * 2003-06-20 2007-06-15 Integragen Sa Methodes de preparation de puces genetiques et utilisations
WO2005048913A2 (en) * 2003-11-24 2005-06-02 Gunnar Westin Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
CA2562833A1 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
WO2005111241A2 (en) * 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
ES2414460T3 (es) * 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
US7771937B2 (en) * 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
US20080293053A1 (en) * 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
SI3345607T1 (sl) 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
MX2010004761A (es) 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
US8716243B2 (en) * 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
DK2286240T3 (en) * 2008-06-03 2016-04-11 Université de Liège Biomarker of osteoarthritis and use thereof
US20110197290A1 (en) 2010-02-11 2011-08-11 Fahrenkrug Scott C Methods and materials for producing transgenic artiodactyls
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
KR20150023670A (ko) * 2012-06-12 2015-03-05 제넨테크, 인크. 조건적 녹아웃 대립유전자의 생성 방법 및 이를 위한 조성물
US8959241B2 (en) * 2012-07-23 2015-02-17 Adobe Systems Incorporated Method and apparatus for performing server-side splicing for live streaming media
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
EP3572513B1 (en) 2013-12-09 2025-09-24 Baylor College of Medicine Hippo and dystrophin complex signaling in cardiomyocyte renewal
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
US20180037909A1 (en) 2016-08-04 2018-02-08 Chang Gung Memorial Hospital, Linkou Modified cancer cell lines and uses thereof
US20190218306A1 (en) * 2018-01-18 2019-07-18 Nalini M. Rajamannan Method of inhibiting ectopic calcification

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
AU7392696A (en) 1995-10-04 1997-04-28 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
JP4271735B2 (ja) * 1997-04-15 2009-06-03 メルク アンド カンパニー，インコーポレイティド 新規のｌｄｌ−レセプター
US6555654B1 (en) * 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
BE1011331A6 (fr) 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
WO1999047529A1 (en) 1998-03-18 1999-09-23 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
JP2002539843A (ja) 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
JP2004515209A (ja) * 2000-04-05 2004-05-27 ゲノム セラピューティックス コーポレーション １１ｑ１３．３の高骨量遺伝子
NZ522600A (en) 2000-05-26 2004-09-24 Genome Therapeutics Corp Regulating lipid levels via the Zmax1 or HBM gene
JP2004517605A (ja) * 2000-06-21 2004-06-17 デルタジェン　インコーポレイテッド 標的化遺伝子破壊を含むトランスジェニックマウス
JP2004507236A (ja) 2000-08-18 2004-03-11 プロスケリア 骨粗鬆症の診断および治療に有用な調節遺伝子および系
BR0209563A (pt) * 2001-05-11 2004-12-07 Genome Theraupeutics Corp ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
DE102007020878B4 (de) 2007-05-04 2020-06-18 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Verfahren zur Prüfung von Umströmungsgeräuschen

Similar Documents

Publication Publication Date Title
Jaworski et al. Collaborative and specialized functions of Robo1 and Robo2 in spinal commissural axon guidance
Moussion et al. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?
Kitajiri et al. Compartmentalization established by claudin-11-based tight junctions in stria vascularis is required for hearing through generation of endocochlear potential
Strotmann et al. Olfactory receptor proteins in axonal processes of chemosensory neurons
Gwack et al. Hair loss and defective T-and B-cell function in mice lacking ORAI1
Labrador et al. The N‐terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling
Han et al. Drosophila glypicans Dally and Dally-like shape the extracellular Wingless morphogen gradient in the wing disc
Lanske et al. PTH/PTHrP receptor in early development and Indian hedgehog—regulated bone growth
Knöll et al. A role for the EphA family in the topographic targeting of vomeronasal axons
Ma et al. Dual branch-promoting and branch-repelling actions of Slit/Robo signaling on peripheral and central branches of developing sensory axons
Thoma-Uszynski et al. BP230-and BP180-specific auto-antibodies in bullous pemphigoid
Hisamatsu et al. Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid
ES2548980T3 (es) Factor de viabilidad neuronal y uso del mismo
Allison et al. Genetic and environmental influences on obesity
Schweitzer et al. Paranemin and the organization of desmin filament networks
JP2009533065A5 (enExample)
Smith et al. Tissue-specific transgenic knockdown of Fos-related antigen 2 (Fra-2) expression mediated by dominant negative Fra-2
Spencer et al. Progressive rod-cone degeneration (PRCD) protein requires N-terminal S-acylation and rhodopsin binding for photoreceptor outer segment localization and maintaining intracellular stability
Reeber et al. Manipulating Robo expression in vivo perturbs commissural axon pathfinding in the chick spinal cord
Sinkó et al. Subcellular localization and N-glycosylation of human ABCC6, expressed in MDCKII cells
Donohoe et al. Transgenic human λ5 rescues the murine λ5 nullizygous phenotype
Koide et al. Formation of granular cytoplasmic aggregates in COS7 cells expressing mutant Cu/Zn superoxide dismutase associated with familial amyotrophic lateral sclerosis
Goto et al. Elimination of epiplakin by gene targeting results in acceleration of keratinocyte migration in mice
Saito et al. Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene
Tran et al. Neuropilin2 regulates the guidance of post-crossing spinal commissural axons in a subtype-specific manner